MedTrace Logo

Evaluation of a Software for the Secondary Prioritization of Patients in the Pediatric Emergency Department

NCT05994196 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1599

Last updated 2023-08-16

No results posted yet for this study

Summary

The goal of this randomized, controlled, open-label trial is to test the use of secondary prioritization software (Optimum®) in the pediatric emergency department (PED).

The aim of this study is to determine:

1. whether the use of this secondary prioritization software (Optimum®) reduces the patients' median length of stay (LOS) in the PED
2. how this software is accepted by the staff. The PED staff will be asked to manage the patients according to the Optimum® software indications (intervention) or according to the standard dashboard (control).

Conditions

  • Length of Stay

Interventions

BEHAVIORAL

Optimum, a secondary prioritization software of patients in the pediatric emergency department (ED)

Optimum®'s purpose is to remove the mental load of prioritization from the Pediatric ED staff. The software first prioritizes the triage of new patients by the ED staff and the first evaluation of a new patient by the medical team. Optimum® then prioritizes blood sample collections and care (for nurses) and checks on imaging results, blood test results or an evaluation by a specialist (for physicians). Lastly, Optimum® prioritizes the final step in patient management by a senior physician, when appropriate.

Sponsors & Collaborators

  • University Hospital, Lille

    lead OTHER

Principal Investigators

  • François Dubos, MD, PhD · Lille University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
3 Days
Max Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-15
Primary Completion
2021-04-23
Completion
2021-04-23

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05994196 on ClinicalTrials.gov